Core Viewpoint - The company has selected ASC36 as a promising candidate for clinical development, expected to be submitted for FDA approval in Q2 2026 for obesity treatment [1] Group 1: Product Development - ASC36 is an amylin receptor agonist developed using AI-assisted structure-based drug discovery and ultra-long-acting platform technologies [1] - The optimized design of ASC36 allows for a longer apparent half-life and higher bioavailability per milligram, supporting monthly subcutaneous administration with a volume not exceeding 1 milliliter [1] - The scalability advantages in manufacturing are highlighted, indicating lower production costs for ASC36 [1] Group 2: Clinical Research Findings - In head-to-head studies with non-human primates, ASC36 demonstrated an average observed half-life of approximately 15 days, three times longer than petrelintide, supporting its potential for monthly dosing in humans [2] - In diet-induced obesity rat studies, ASC36 achieved a weight reduction of 10.01%, compared to 5.25% for petrelintide, indicating a relative improvement of 91% in weight loss effectiveness [2] - The superior weight loss effect per milligram of peptide may further enhance the cost-effectiveness of ASC36 in large-scale production [2]
歌礼制药-B(01672)选定同类最佳每月一次皮下注射胰淀素受体激动剂 ASC36进入临床开发阶段